Market Overview:
The global fibrinogen deficiency drug market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of thrombotic disorders, rising awareness about fibrinogen deficiency drugs, and technological advancements in the field of fibrinogen replacement therapy. Based on type, the global fibrinogen deficiency drug market can be segmented into three categories: Fibrinogen, Fibrinogen Concentrate, and Others. The Others category includes products such as cryoprecipitate and fresh frozen plasma (FFP). FFP is expected to account for a major share of the global fibrinogen deficiency drug market due to its high demand for treating various bleeding disorders. Based on application, the global fibrinogen deficiency drug market can be segmented into three categories: Hospital, Clinic, and Others. The Hospital category is expected to account for a major share of the global fibrinogen deficiency drug market due to increased use of these drugs in hospitals for treatment purposes.
Product Definition:
A drug used to treat a deficiency in the blood protein fibrinogen. Fibrinogen is important for blood clotting and helps to stop bleeding.
Fibrinogen:
Fibrinogen is a blood protein and it's deficiency leads to bleeding disorder known as Fibrinogen Deficiency (FGD) or Coagulation Disorder. It is also used in the treatment of liver diseases, pulmonary embolism, deep vein thrombosis (DVT), and heart attack. The drug was approved by the U.
Fibrinogen Concentrate:
Fibrinogen is a protein that is found in the blood. It helps maintain the structural integrity of blood vessels and acts as an adhesive to help coagulation (clot formation) occur more quickly after injury or surgery. The normal level of fibrinogen in plasma is 40-80 mg/dL and can be increased to 150-300 mg/dL by oral intake, via infusion, or through intravenous injection.
Application Insights:
The others segment held the largest share of the global market in 2017. This segment includes fibrin sealants, tissue sealants and adhesives. These products are used for various applications such as burns, surgical dressings and skin grafts. The increasing prevalence of trauma cases due to road accidents, wars and other causes is expected to boost product demand over the forecast period.
Fibulinogen deficiency accounted for a significant share in North America market owing to rising adoption of advanced wound care procedures among patients suffering from diabetes or chronic wounds at risk of developing complications related with their health condition.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and high adoption rate for advanced therapeutics are some factors responsible for its large share. Moreover, increasing prevalence of thrombosis and cardiovascular diseases is also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure by governments as well as private sectors in order to improve patient care standards and treatment efficacy across various disorders including fibrinogen deficiency. In addition, growing awareness about early diagnosis among patients will further boost revenue generation prospects during the estimated time span.
Growth Factors:
- Increasing incidence of thromboembolic disorders: The global Fibrinogen Deficiency Drug market is expected to grow at a CAGR of 5.5% during the forecast period owing to the increasing incidence of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism.
- Growing geriatric population: The geriatric population is more susceptible to developing Fibrinogen Deficiency Drug-related diseases, which is expected to drive the growth of the market during the forecast period.
- Technological advancements in diagnosis and treatment: Technological advancements in diagnosis and treatment are anticipated to boost growth prospects for the global Fibrinogen Deficiency Drug market during the forecast period. For instance, introduction of novel drugs such as recombinant human fibrinogen concentrate (FibriLyte) has revolutionized treatment options for patients with fibrinogen deficiency disorder (FDD). This has led to an increase in demand for these drugs, thereby propelling growth prospects for this market segment over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Fibrinogen Deficiency Drug Market Research Report
By Type
Fibrinogen, Fibrinogen Concentrate, Others
By Application
Hospital, Clinic, Others
By Companies
Biotest AG, China Biologic Products, Inc., Grifols, S.A., LFB S.A., Octapharma AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
200
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global Fibrinogen Deficiency Drug Market Report Segments:
The global Fibrinogen Deficiency Drug market is segmented on the basis of:
Types
Fibrinogen, Fibrinogen Concentrate, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biotest AG
- China Biologic Products, Inc.
- Grifols, S.A.
- LFB S.A.
- Octapharma AG
Highlights of The Fibrinogen Deficiency Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Fibrinogen
- Fibrinogen Concentrate
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fibrinogen Deficiency Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fibrinogen deficiency drug is a medication used to treat fibrinogen levels in the blood. It is also used to prevent or reduce the risk of blood clots.
Some of the key players operating in the fibrinogen deficiency drug market are Biotest AG, China Biologic Products, Inc., Grifols, S.A., LFB S.A., Octapharma AG.
The fibrinogen deficiency drug market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fibrinogen Deficiency Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fibrinogen Deficiency Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fibrinogen Deficiency Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fibrinogen Deficiency Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fibrinogen Deficiency Drug Market Size & Forecast, 2020-2028
4.5.1 Fibrinogen Deficiency Drug Market Size and Y-o-Y Growth
4.5.2 Fibrinogen Deficiency Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Fibrinogen
5.2.2 Fibrinogen Concentrate
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fibrinogen Deficiency Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fibrinogen Deficiency Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Fibrinogen
9.6.2 Fibrinogen Concentrate
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Fibrinogen
10.6.2 Fibrinogen Concentrate
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Fibrinogen
11.6.2 Fibrinogen Concentrate
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Fibrinogen
12.6.2 Fibrinogen Concentrate
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Fibrinogen
13.6.2 Fibrinogen Concentrate
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fibrinogen Deficiency Drug Market: Competitive Dashboard
14.2 Global Fibrinogen Deficiency Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biotest AG
14.3.2 China Biologic Products, Inc.
14.3.3 Grifols, S.A.
14.3.4 LFB S.A.
14.3.5 Octapharma AG
